
Yanan Wang

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2551104/publications.pdf Version: 2024-02-01



YANAN WANC

#	Article	IF	CITATIONS
1	Butyrate reduces appetite and activates brown adipose tissue via the gut-brain neural circuit. Gut, 2018, 67, 1269-1279.	6.1	401
2	Combined Deletion of Macrophage ABCA1 and ABCG1 Leads to Massive Lipid Accumulation in Tissue Macrophages and Distinct Atherosclerosis at Relatively Low Plasma Cholesterol Levels. Arteriosclerosis, Thrombosis, and Vascular Biology, 2008, 28, 258-264.	1.1	178
3	Central GLP-1 receptor signalling accelerates plasma clearance of triacylglycerol and glucose by activating brown adipose tissue in mice. Diabetologia, 2015, 58, 2637-2646.	2.9	100
4	Exendinâ€4 decreases liver inflammation and atherosclerosis development simultaneously by reducing macrophage infiltration. British Journal of Pharmacology, 2014, 171, 723-734.	2.7	95
5	BMP7 Activates Brown Adipose Tissue and Reduces Diet-Induced Obesity Only at Subthermoneutrality. PLoS ONE, 2013, 8, e74083.	1.1	82
6	Overexpression of Angiopoietin-Like Protein 4 Protects Against Atherosclerosis Development. Arteriosclerosis, Thrombosis, and Vascular Biology, 2013, 33, 1529-1537.	1.1	79
7	GLP-1 Receptor Activation Inhibits VLDL Production and Reverses Hepatic Steatosis by Decreasing Hepatic Lipogenesis in High-Fat-Fed APOE*3-Leiden Mice. PLoS ONE, 2012, 7, e49152.	1.1	71
8	Cholesteryl Ester Transfer Protein Influences High-Density Lipoprotein Levels and Survival in Sepsis. American Journal of Respiratory and Critical Care Medicine, 2019, 199, 854-862.	2.5	62
9	Plasma cholesteryl ester transfer protein is predominantly derived from Kupffer cells. Hepatology, 2015, 62, 1710-1722.	3.6	60
10	Inhibition of Cholesteryl Ester Transfer Protein Preserves High-Density Lipoprotein Cholesterol and Improves Survival in Sepsis. Circulation, 2021, 143, 921-934.	1.6	55
11	Resveratrol protects against atherosclerosis, but does not add to the antiatherogenic effect of atorvastatin, in APOE*3-Leiden.CETP mice. Journal of Nutritional Biochemistry, 2013, 24, 1423-1430.	1.9	49
12	CETP (Cholesteryl Ester Transfer Protein) Concentration. Circulation Genomic and Precision Medicine, 2018, 11, e002034.	1.6	44
13	Inhibition of Δ24-dehydrocholesterol reductase activates pro-resolving lipid mediator biosynthesis and inflammation resolution. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 20623-20634.	3.3	38
14	Diabetic Nephropathy Alters the Distribution of Circulating Angiogenic MicroRNAs Among Extracellular Vesicles, HDL, and Ago-2. Diabetes, 2019, 68, 2287-2300.	0.3	37
15	Short-term high-fat diet increases macrophage markers in skeletal muscle accompanied by impaired insulin signalling in healthy male subjects. Clinical Science, 2015, 128, 143-151.	1.8	34
16	Pharmacological treatment with FGF21 strongly improves plasma cholesterol metabolism to reduce atherosclerosis. Cardiovascular Research, 2022, 118, 489-502.	1.8	34
17	Prolonged Caloric Restriction in Obese Patients With Type 2 Diabetes Mellitus Decreases Plasma CETP and Increases Apolipoprotein AI Levels Without Improving the Cholesterol Efflux Properties of HDL. Diabetes Care, 2011, 34, 2576-2580.	4.3	33
18	Mendelian randomization reveals unexpected effects of CETP on the lipoprotein profile. European Journal of Human Genetics, 2019, 27, 422-431.	1.4	30

YANAN WANG

#	Article	IF	CITATIONS
19	Anacetrapib reduces (V)LDL cholesterol by inhibition of CETP activity and reduction of plasma PCSK9. Journal of Lipid Research, 2015, 56, 2085-2093.	2.0	27
20	Lipopolysaccharide Lowers Cholesteryl Ester Transfer Protein by Activating F4/80 ⁺ Clec4f ⁺ Vsig4 ⁺ Ly6C ^{â^'} Kupffer Cell Subsets. Journal of the American Heart Association, 2018, 7, .	1.6	27
21	Atorvastatin accelerates clearance of lipoprotein remnants generated by activated brown fat to further reduce hypercholesterolemia and atherosclerosis. Atherosclerosis, 2017, 267, 116-126.	0.4	23
22	Colesevelam enhances the beneficial effects of brown fat activation on hyperlipidaemia and atherosclerosis development. Cardiovascular Research, 2020, 116, 1710-1720.	1.8	22
23	A Novel Role for CETP as Immunological Gatekeeper: Raising HDL to Cure Sepsis?. Trends in Endocrinology and Metabolism, 2020, 31, 334-343.	3.1	22
24	Niacin reduces plasma CETP levels by diminishing liver macrophage content in CETP transgenic mice. Biochemical Pharmacology, 2012, 84, 821-829.	2.0	21
25	Pioglitazone Decreases Plasma Cholesteryl Ester Transfer Protein Mass, Associated With a Decrease in Hepatic Triglyceride Content, in Patients With Type 2 Diabetes. Diabetes Care, 2010, 33, 1625-1628.	4.3	20
26	Male apoE*3-Leiden.CETP mice on high-fat high-cholesterol diet exhibit a biphasic dyslipidemic response, mimicking the changes in plasma lipids observed through life in men. Physiological Reports, 2017, 5, e13376.	0.7	19
27	Differential Complement Activation Pathways Promote C3b Deposition on Native and Acetylated LDL thereby Inducing Lipoprotein Binding to the Complement Receptor 1. Journal of Biological Chemistry, 2014, 289, 35421-35430.	1.6	16
28	Both Transient and Continuous Corticosterone Excess Inhibit Atherosclerotic Plaque Formation in APOE*3-Leiden.CETP Mice. PLoS ONE, 2013, 8, e63882.	1.1	14
29	In vivo and in silico dynamics of the development of Metabolic Syndrome. PLoS Computational Biology, 2018, 14, e1006145.	1.5	12
30	Impact of rural-urban environment on metabolic profile and response to a 5-day high-fat diet. Scientific Reports, 2018, 8, 8149.	1.6	11
31	Overexpression of apolipoprotein AV in the liver reduces plasma triglyceride and cholesterol but not HDL in ApoE deficient mice. Biochemical and Biophysical Research Communications, 2006, 346, 14-18.	1.0	9
32	Serum CETP concentration is not associated with measures of body fat: The NEO study. Atherosclerosis, 2016, 246, 267-273.	0.4	9
33	Cannabinoid type 1 receptor inverse agonism attenuates dyslipidemia and atherosclerosis in APOEâ^—3-Leiden.CETP mice. Journal of Lipid Research, 2021, 62, 100070.	2.0	9
34	Beneficial effects of brown fat activation on top of PCSK9 inhibition with alirocumab on dyslipidemia and atherosclerosis development in APOE*3-Leiden.CETP mice. Pharmacological Research, 2021, 167, 105524.	3.1	9
35	Enhanced atherothrombotic formation after oxidative injury by FeCl3 to the common carotid artery in severe combined hyperlipidemic mice. Biochemical and Biophysical Research Communications, 2009, 385, 563-569.	1.0	7
36	CETP expression reverses the reconstituted HDL-induced increase in VLDL. Journal of Lipid Research, 2011, 52, 1533-1541.	2.0	7

YANAN WANG

#	Article	IF	CITATIONS
37	Acute Central Neuropeptide Y Administration Increases Food Intake but Does Not Affect Hepatic Very Low-Density Lipoprotein (Vldl) Production in Mice. PLoS ONE, 2013, 8, e55217.	1.1	7
38	Computational modelling of energy balance in individuals with Metabolic Syndrome. BMC Systems Biology, 2019, 13, 24.	3.0	6
39	Hepatic Scavenger Receptor Class B Type 1 Knockdown Reduces Atherosclerosis and Enhances the Antiatherosclerotic Effect of Brown Fat Activation in APOE*3-Leiden.CETP Mice. Arteriosclerosis, Thrombosis, and Vascular Biology, 2021, 41, 1474-1486.	1.1	6
40	Ritonavir protects against the development of atherosclerosis in APOE*3-Leiden mice. Atherosclerosis, 2010, 210, 381-387.	0.4	5
41	Metabolic liver inflammation in obesity does not robustly decrease hepatic and circulating CETP. Atherosclerosis, 2018, 275, 149-155.	0.4	5
42	Hepatic triglyceride content does not affect circulating CETP: lessons from a liraglutide intervention trial and a population-based cohort. Scientific Reports, 2019, 9, 9996.	1.6	5
43	The Iminosugar AMP-DNM Improves Satiety and Activates Brown Adipose Tissue Through GLP1. Diabetes, 2019, 68, 2223-2234.	0.3	5
44	Butyrate via the gut-brain neural circuit reduces appetite and activates brown adipose tissue. Atherosclerosis, 2018, 275, e15-e16.	0.4	4
45	Continuous Light Does Not Affect Atherosclerosis in APOE*3-Leiden.CETP Mice. Journal of Biological Rhythms, 2020, 35, 598-611.	1.4	4
46	Electrical Neurostimulation Promotes Brown Adipose Tissue Thermogenesis. Frontiers in Endocrinology, 2020, 11, 567545.	1.5	4
47	The aminoterminal 1–185 domain of human apolipoprotein E suffices for the de novo biogenesis of apoE-containing HDL-like particles in apoA-I deficient mice. Atherosclerosis, 2011, 219, 116-123.	0.4	2
48	Butyrate via the gut-brain neuronal circuit reduces appetite and activates brown adipose tissue. Atherosclerosis, 2017, 263, e85.	0.4	2
49	A hierarchical dynamic model used for investigating feed efficiency and its relationship with hepatic gene expression in APOE*3â€Leiden.CETP mice. Physiological Reports, 2021, 9, e14832.	0.7	2
50	5 THE GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST EXENDIN-4 INHIBITS VLDL BIOSYNTHESIS AND SECRETION IN APOE*3-LEIDEN MICE. Atherosclerosis Supplements, 2011, 12, 2.	1.2	0
51	172 NIACIN, ATORVASTATIN AND FENOFIBRATE DECREASE PLASMA CETP BY REDUCTION OF THE HEPATIC MACROPHAGE CONTENT IN APOE*3-LEIDEN.CETP MICE. Atherosclerosis Supplements, 2011, 12, 38.	1.2	0
52	PS16 - 81. Chronic niacin treatment of ApoE*3Leiden-CETP mice results in impaired insulin mediated repression of lipolysis in isolated adipocytes. Nederlands Tijdschrift Voor Diabetologie, 2011, 9, 146-146.	0.0	0
53	PS16 - 82. GLP-1 receptor agonism inhibits VLDL production and reverses hepatic steatosis by decreasing hepatic lipogenesis in high fat diet-fed APOE*3-Leiden mice. Nederlands Tijdschrift Voor Diabetologie, 2011, 9, 147-147.	0.0	0
54	PS1 - 5. The GLP-1 receptor agonist exendin-4 reduces atherosclerosis development and NASH in APOE*3.Leiden.CETP mice. Nederlands Tijdschrift Voor Diabetologie, 2012, 10, 102-102.	0.0	0

Yanan Wang

#	Article	IF	CITATIONS
55	PS19 - 90. BMP-7 reduces high fat diet-induced adiposity in mice by activating brown adipose tissue in a sympathetic-dependent way: Implications for obesity. Nederlands Tijdschrift Voor Diabetologie, 2012, 10, 163-163.	0.0	0
56	PS13 - 7. Plasma cholesteryl ester transfer protein: a biomarker for hepatic macrophages. Nederlands Tijdschrift Voor Diabetologie, 2013, 11, 195-195.	0.0	0
57	Butyrate via the gut-brain circuit reduces appetite and activates brown adipose tissue. Atherosclerosis, 2016, 252, e250.	0.4	0
58	LPS reduces hepatic CETP expression by mature resident macrophages. Atherosclerosis, 2017, 263, e8-e9.	0.4	0
59	Statin treatment potentiates the lipid-lowering and anti-atherogenic effect of bat activation by accelerating lipoprotein remnant clearance. Atherosclerosis, 2017, 263, e212.	0.4	0
60	Circulating cetp is not related to the hepatic triglyceride content: Lessons from a liraglutide intervention trial and a population-based cohort. Atherosclerosis, 2018, 275, e60.	0.4	0
61	Bile acid sequestrant colesevelam enhances beneficial effects of brown fat activation on cholesterol metabolism in APOE*3-Leiden.CETP mice. Atherosclerosis, 2018, 275, e23.	0.4	0
62	Genetically-determined CETP concentration decreases large HDL and increases small VLDL without affecting LDL. Atherosclerosis, 2018, 275, e25.	0.4	0
63	FXR activation normalizes dyslipidemia and alleviates obesity in western-type diet–fed APOE*3-Leiden.CETP transgenic mice. Atherosclerosis, 2018, 275, e10.	0.4	0
64	Δ24-Dehydrocholesterol reductase (DHCR24): A novel target for the treatment of nash. Atherosclerosis, 2020, 315, e11.	0.4	0